| Field | Specification |
|---|---|
| Target | |
| Alternative names | Gasdermin-D; Gasdermin domain-containing protein 1; GSDMD; DFNA5L; GSDMDC1 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human GSDMD recombinant protein (Position: M1-H484). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects gasdermin-D (gene GSDMD) in human samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 52.8 kDa; the supplier reports observed bands at 30, 53 kDa.
Gasdermin D (GSDMD) is the main executor of pyroptosis, an inflammatory form of programmed cell death. Cleavage by inflammatory caspases such as caspase-1 and caspase-11 (caspase-4/5 in humans) frees its N-terminal fragment, which inserts into membranes and forms large pores. These pores release IL-1β and IL-18 and cause cell lysis, making GSDMD central to inflammasome and innate immunity research.
| Target | Gasdermin-D (gene GSDMD; UniProt P57764, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 52.8 kDa |
| Observed MW | 30, 53 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human Jurkat cells, human MOLT4 cells, human THP-1 cells, human THP-1(+TPA+LPS) cells, human THP-1- WT cells, human THP-1-GSDMD KO cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 10% SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human prostate cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): PC-3 cells.
Samples with a confirmed signal (flow cytometry): U2OS cells.
Immunogen
Recombinant human GSDMD fragment (Met1–His484), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. UniProt places gasdermin-D in the [Gasdermin-D]: Cytoplasm and inflammasome. Tissue expression noted by UniProt (human): Expressed in the suprabasal cells of esophagus, as well as in the isthmus/neck, pit, and gland of the stomach, suggesting preferential expression in differentiating cells. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Yi Chen et al. (2026) IER3 Promotes Non-Small Cell Lung Cancer Malignancy by Suppressing Ferroptosis via the AKT/GSK3β/NRF2 Pathway. Free Radical Biology and Medicine. 10.1016/j.freeradbiomed.2026.01.029
Jingjing Liu et al. (2021) Terazosin Stimulates Pgk1 to Remedy Gastrointestinal Disorders. International Journal of Molecular Sciences. 10.3390/ijms23010416
Jingjing Liu et al. (2025) Repurposing Lamivudine: A novel therapeutic strategy for ischemic stroke targeting the glycolytic enzyme Pgk1. Biochemical Pharmacology. 10.1016/j.bcp.2025.117529
Ming-Wei Fan et al. (2026) Electroacupuncture protects gastric Cajal cells by reducing macrophage pyroptosis in diabetic gastroparesis. World Journal of Diabetes. 10.4239/wjd.v17.i2.114252
Qianru Chi et al. (2024) In vitro and in silico analyses reveal the toxicity of metolachlor to grass carp hepatocytes and the antagonism of melatonin. Pesticide Biochemistry and Physiology. 10.1016/j.pestbp.2024.105930
Xiaoyan Zhang et al. (2023) Metformin inhibits EV71‑induced pyroptosis by upregulating DEP domain‑containing mTOR‑interacting protein. Experimental and Therapeutic Medicine. 10.3892/etm.2023.12087
